CompuVax
Pioneering the future of viral vaccines with engineered antigens since 2013
Pioneering the future of viral vaccines with engineered antigens since 2013
CompuVax is a pioneering company in the field of viral vaccines, specializing in engineered antigens. Since its establishment in 2013 in Del Mar, California, CompuVax has been dedicated to becoming a leading source of engineered antigens, which are crucial components for future viral vaccines. The company received a $500.00K Seed Round investment on the 01 April 2015 to support its innovative endeavors. CompuVax operates within the Biotechnology, Health Care, and Information Technology industries. With its focus on cutting-edge advancements in viral vaccine development, CompuVax is poised for significant growth and impact in the fight against infectious diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $500.00K | - | 01 Apr 2015 |
No recent news or press coverage available for CompuVax.
We care about your data, and we'd love to use cookies make your experience better.
